表紙
市場調査レポート

類鼻疽- パイプライン製品の分析

Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 321927
出版日 ページ情報 英文 62 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
類鼻疽- パイプライン製品の分析 Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H1 2016
出版日: 2016年05月31日 ページ情報: 英文 62 Pages
概要

類鼻疽は、グラム陰性の好気性双極桿菌で土壌中に生息するバクテリアによっておこる感染症です。このバクテリアは吸入、摂取、傷口などから動物およびヒト双方に感染し、症状は発熱、咳、胸痛、頭痛、食欲不振などがあります。

当レポートでは、類鼻疽に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

類鼻疽の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究所別

パイプライン製品の概要

  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究所別

治療薬の開発に従事している企業

  • Bavarian Nordic A/S 14
  • Emergent BioSolutions Inc. 15
  • Evolva SA 16
  • Soligenix, Inc. 17
  • Syntiron LLC 18

治療薬の評価

  • 単独療法の製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • Burkholderia pseudomallei vaccine
  • burkholderia vaccine
  • EV-035
  • GC-072
  • SGX-101
  • SGX-942
  • SGX-943
  • Small Molecules to Inhibit FtsZ Protein for Bacterial Infections
  • Small Molecules to Inhibit InhA for Infectious Diseases

最新のパイプライン製品情報

開発休止中のプロジェクト

製品開発のマイルストーン

  • 注目のニュースおよびプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8127IDB

Summary

Global Markets Direct's, 'Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H1 2016', provides an overview of the Burkholderia pseudomallei Infections (Melioidosis) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Burkholderia pseudomallei Infections (Melioidosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Burkholderia pseudomallei Infections (Melioidosis) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Burkholderia pseudomallei Infections (Melioidosis)
  • The report reviews pipeline therapeutics for Burkholderia pseudomallei Infections (Melioidosis) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Burkholderia pseudomallei Infections (Melioidosis) therapeutics and enlists all their major and minor projects
  • The report assesses Burkholderia pseudomallei Infections (Melioidosis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Burkholderia pseudomallei Infections (Melioidosis)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Burkholderia pseudomallei Infections (Melioidosis)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Burkholderia pseudomallei Infections (Melioidosis) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Burkholderia pseudomallei Infections (Melioidosis) Overview
    • Therapeutics Development
  • Pipeline Products for Burkholderia pseudomallei Infections (Melioidosis) - Overview
  • Pipeline Products for Burkholderia pseudomallei Infections (Melioidosis) - Comparative Analysis
  • Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics under Development by Companies
  • Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics under Investigation by Universities/Institutes
  • Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Products Glance
    • Early Stage Products
  • Burkholderia pseudomallei Infections (Melioidosis) - Products under Development by Companies
  • Burkholderia pseudomallei Infections (Melioidosis) - Products under Investigation by Universities/Institutes
  • Burkholderia pseudomallei Infections (Melioidosis) - Companies Involved in Therapeutics Development
    • Bavarian Nordic A/S
    • Emergent BioSolutions Inc.
    • Grifols, S.A.
    • Soligenix, Inc.
    • Syntiron LLC
  • Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ARD-3100 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ARD-3150 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Burkholderia pseudomallei vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Burkholderia vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dusquetide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EV-035 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GC-072 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • melioidosis vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SGX-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SGX-943 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit InhA for Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Burkholderia pseudomallei Infections (Melioidosis) - Recent Pipeline Updates
  • Burkholderia pseudomallei Infections (Melioidosis) - Dormant Projects
  • Burkholderia pseudomallei Infections (Melioidosis) - Discontinued Products
  • Burkholderia pseudomallei Infections (Melioidosis) - Product Development Milestones
    • Featured News & Press Releases
      • Feb 11, 2015: Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
      • Aug 14, 2014: US DTRA to fund preclinical work on Evolva's antibiotic GC-072
      • Feb 21, 2014: Bavarian Nordic's MVA-BN Vaccine Platform Selected By U.S. Department Of Defense For New Vaccine Development
      • Feb 14, 2014: Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Burkholderia pseudomallei Infections (Melioidosis), H1 2016
  • Number of Products under Development for Burkholderia pseudomallei Infections (Melioidosis) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Bavarian Nordic A/S, H1 2016
  • Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Emergent BioSolutions Inc., H1 2016
  • Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Grifols, S.A., H1 2016
  • Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Soligenix, Inc., H1 2016
  • Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Syntiron LLC, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Burkholderia pseudomallei Infections (Melioidosis) Therapeutics - Recent Pipeline Updates, H1 2016
  • Burkholderia pseudomallei Infections (Melioidosis) - Dormant Projects, H1 2016
  • Burkholderia pseudomallei Infections (Melioidosis) - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Burkholderia pseudomallei Infections (Melioidosis) - Comparative Analysis, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top